摘要
目的研究选择性环氧化酶-2(COX-2)抑制剂塞来昔布联合5-Fu对SGC-7901人胃癌细胞增殖及Bcl-2、Bax表达的影响。方法以SGC-7901人胃癌细胞为研究对象,运用不同浓度的塞来昔布联合5-Fu,采用MTT法测定塞来昔布及其与5-Fu联合对胃癌细胞生长的影响,流式细胞仪(FCM)检测处理后细胞周期和凋亡的变化,免疫组化检测Bcl-2、Bax的表达。结果塞来昔布联合5-Fu对胃癌细胞均有抑制作用,且联合用药及单药的抑制率与对照组比较差异有统计学意义(P<0.05);流式细胞学检测到凋亡峰,其抑制作用呈时间-剂量依赖性;处理后的胃癌细胞进行免疫组化检测,发现联合用药组有更显著的Bcl-2表达下降和Bax表达增强。结论塞来昔布与5-Fu联合对胃癌细胞有协同抑制作用,其机制可能与改变Bcl-2和Bax的表达水平有关。
Objective To investigate the effects of Celecoxib,a selective COX-2 inhibitor,with 5-Fu on cell proliferation,Bcl-2 and Bax Expression and apoptos is in SGC-7901 human gastric cancer cell line and to explore its anti-neoplasm mechanism. Methods MTT assay was used to determine cell proliferation after incubation in different concentrations of celecoxib with 5-Fu. The effect of celecoxib with 5-Fu on cell cycle changes and apoptosis of cells was studied by flow cytometry （FCM）. The immunohistochemistry measured the expression of Bcl-2 and Bax proteins. Results Celecoxibs with 5-Fu significantly inhibited the growth of gastric cancer cells and elevated the inhibiting rate compared with control group（P〈0.05）. Flow cytometry apoptotic peak was detected, the inhibition was time-dose dependent;Treated gastric cancer cells were detected by immunobistochemistry and found that the combination group had more significant decreased expression of Bcl-2 and Bax expression increased. Conclusion Celecoxib combined with 5-Fu had synergistic inhibitory effect on gastric cancer cells,which may change the Bcl-2 and Bax expression and the level.
出处
《中国现代医生》
2011年第7期10-11,15,共3页
China Modern Doctor
